# NCT03226249 (NCT03226249)

> PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03226249
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: Northwestern University
- Conditions: Classical Hodgkin Lymphoma; Lymphocyte-Depleted Classical Hodgkin Lymphoma; Lymphocyte-Rich Classical Hodgkin Lymphoma; Mixed Cellularity Classical Hodgkin Lymphoma; Nodular Sclerosis Classical Hodgkin Lymphoma
- Interventions: Computed Tomography; Dacarbazine; Doxorubicin Hydrochloride; Fludeoxyglucose F-18; Laboratory Biomarker Analysis; Pembrolizumab; Positron Emission Tomography; Vinblastine Sulfate
- Enrollment: 30
- Primary outcome: Complete Response (CR) With Pembrolizumab Treatment Alone

## Indexed commentary on NCT03226249 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03226249